glp-1 novo Novo's Wegovy becomes first drug approved for MASH Novo Nordisk's GLP-1 weight-loss pill

Implications and Future Research GLP-1 agonists offer significant benefits for weight loss and metabolic health, but their potential effects on sexual function should not be overlooked

Many people seeking help for obesity have already made repeated attempts to lose weight through diet and exercise, often without long-term results

Wealthier nations often have higher prevalence rates, while the Mediterranean and Eastern European countries show the most overweight and obese people

(2025) 8:e70045

Diab Metab Syndr Obes 2021;14:163145

Tirzepatide: a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) dual agonist in development for the treatment of type 2 diabetes